Pancreatic ductal adenocarcinoma (PDA) metastases are poorly understood, limiting the effectiveness of current treatments. An improved understanding of the mechanisms by which PDA metastasizes is critical for the development of effective treatments specific for this disease. We recently identified a PDA-associated antigen, annexin A2 (ANXA2), and demonstrated that tyrosine 23-phosphorylation-dependent cell-surface translocation of ANXA2 is critical for TGFbeta-Rho mediated epithelia-to-mesenchymal transition, invasion and metastasis of PDAs. This proposal aims to delineate the upstream and downstream pathways of ANXA2 to achieve our ultimate goal of identifying new therapeutic targets for PDA treatment. In particular, we hypothesize that two paracrine stromal-to-epithelial axes - the Hedgehog-Insulin-like growth factor I receptor pathway and the hepatocyte growth factor/c-met signaling - form a functional link between PDA stroma and epithelial compartments, resulting in ANXA2 phosphorylation. To understand the effector pathways whereby PDA metastases are promoted following the activation of ANXA2 by phosphorylation, our preliminary studies have led to the second part of our hypothesis that ANXA2 regulates PDA invasion and metastasis through Sema3d/Plxnd1, both belonging to an axon guidance pathway. We therefore propose two aims to test these hypotheses.
Specific Aim 1 will elucidate the network of signals that originate in the stroma and result in ANXA2 translocation to the surface of PDA cells.
Specific Aim 2 will delineate the downstream effectors of ANXA2 within PDA tumor cells that mediate metastatic spread through axon guidance molecules. The end result will be the elucidation of the complex network of signals that results in cross-talk between the PDA and its microenvironment, and that are mediated through ANXA2 to control PDA invasion and metastasis formation. This in turn, will provide new targets against which to develop novel interventions that disrupt the communication, and in doing so, abrogate tumor progression and metastases.

Public Health Relevance

Recent studies have identified biologic signals that represent cross talk between pancreatic tumors and their surrounding cancer supporting cells (stroma) within the tumor microenvironment. These signals serve to promote tumor progression and metastases. A detailed understanding of this complex signaling network will uncover new targets against which to develop novel interventions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA169702-02
Application #
8712421
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Jhappan, Chamelli
Project Start
2013-08-02
Project End
2018-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
2
Fiscal Year
2014
Total Cost
$326,066
Indirect Cost
$124,791
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Zhang, Jiajia; Quadri, Shafat; Wolfgang, Christopher L et al. (2018) New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 6:
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Rucki, Agnieszka A; Foley, Kelly; Zhang, Pingbo et al. (2017) Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. Cancer Res 77:41-52
Saung, May Tun; Zheng, Lei (2017) Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther 39:2125-2134
Murphy, Adrian G; Foley, Kelly; Rucki, Agnieszka A et al. (2017) Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. Oncotarget 8:106405-106414
Zheng, Lei (2017) PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst 109:
Pea, Antonio; Yu, Jun; Rezaee, Neda et al. (2017) Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg 266:133-141
Rucki, Agnieszka A; Xiao, Qian; Muth, Stephen et al. (2017) Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. Mol Cancer Ther 16:2399-2409
Zhang, Meng-Wen; Fujiwara, Kenji; Che, Xu et al. (2017) DNA methylation in the tumor microenvironment. J Zhejiang Univ Sci B 18:365-372

Showing the most recent 10 out of 38 publications